The lancet. Gastroenterology & hepatologyHumansColitisUlcerativeChildMale
Efficacy and safety of mirikizumab in paediatric participants with moderately-to-severely active ulcerative colitis (SHINE-1): a multicentre, open-label, non-randomised phase 2 trial.
Jess L Kaplan, Athos Bousvaros, Dan Turner, Marla Dubinsky, Amy Larkin, Jordan Johns, Yuki Otani, Wallace Crandall, Wendy J Komocsar, Jeffrey S Hyams
Published: 202610.1016/S2468-1253(25)00196-7
Abstract
BACKGROUND: Mirikizumab, a humanised immunoglobulin G4 monoclonal antibody, targets the p19 subunit of IL-23, with demonstrated efficacy and safety in adults with ulcerative colitis and Crohn's disease. This study evaluated the pharmacokinetics, effi…
Preview only. Read the full abstract at the source